|
Background Information
In the middle of the
global economic downturn, the central nervous system
drug market is booming. Population growth, better
diagnosis and unmet clinical needs mean 70 companies
are vying for a market spanning from pain to
schizophrenia to obesity.
And, as more of us live longer,
the number of people with age-related brain diseases is
spiraling. In Europe and the United States alone, this will mean
13.2 million Alzheimer’s and 16.2 million Parkinson’s disease
sufferers- worldwide- by 20502.
If effective therapies for such
neurodegenerative disorders are not found soon, the fi nancial,
societal and emotional costs will be staggering. At the same
time, many basic issues in CNS R&D remain unresolved, such as
reducing production schedules and compound attrition.
By attending this conference, you
will understand how these challenges in CNS drug development are
being overcome, as well as:
- How can drug delivery across
the blood-brain barrier be improved?
- Have new biomarkers been
identifi ed to track disease existence or progression?
- What are the future roles for
stem cell and regenerative therapies in lead optimisation?
- Will creating human-animal
cytoplasmic hybrid embryos bring new therapies for
neurodegenerative diseases?
- How can new medicines that
improve cognition be validated in clinical trials?
- Should these drugs be
available to the general public?
- How can we overcome patient
heterogeneity?
- Is there a future for
pharmacogenomics in psychiatry?
I look forward to seeing you
at the conference.
Yours sincerely
John Shah
Conference Producer
Key Speakers
Jacqueline Hunter, Senior Vice President, Science Environment
Development, GlaxoSmithKline
Johan Luthman, TA Head, Neurology, Autoimmune & Infl ammatory
Diseases, Merck Serono
Mark Tricklebank, Director, Senior Research Fellow- Psychiatric
Disorders Drug Hunting Team, Lilly UK
Leslie Iversen, Department of Pharmacology, University of Oxford
Stephen Minger, Director, Stem Cell Biology Laboratory, King’s
College London
Simmone Braggio, Director, Neuroscience CEDD DMPK,
GlaxoSmithKline
Peter Jenner, Chief Scientifi c Offi cer, Proximagen
Keith Wesnes, Chief Executive, Cognitive Drug Research
Ann Hayes, Owner, The Ann Hayes Consultancy
Fabrizio Gasparini, Senior Research Investigator, Novartis
John Sinden, Chief Scientifi c Offi cer, ReNeuron
Claude Wischik, Executive Chairman, TauRx Therapeutics
Anders Haegerstand, Chief Scientifi c Offi cer, NeuroNova
Will Spooren, Project Leader, Drug Discovery, Hoffmann-La Roche
Jose de Leon, Director, Research Offi ce, Eastern State
Hospital, University of Kentucky
Steve England, Associate Research Fellow, Pfi zer
Who will be there?
Heads, Directors, Senior VPs,
CSOs and Project leaders in:
- CNS Clinical Discovery/Nervous
System Research
- Neuroscience
- Neurology
- Psychiatry/Molecular
Psychiatry
- Drug Discovery/Drug R&D/Drug
Design
- Emerging Targets/Lead
Optimisation
- Stem Cell Research/Stem Cell
Regulatory Affairs
- Therapeutics and Molecular
Profi ling
- Pain Management
- Protein Technologies
- Pre-Clinical/Clinical R&D
-
Genomics/Proteomics/Bioinformatics/Neuroinformatics
- Translational Medicine
- Global Marketing and Medicine
- Disease Genetics
- Pharmacology
- Imaging
- Immunology/immunotherapy
Back To Top |
To be held at 15th - 16th December
2008, BSG Conference Centre, London, UK
